Dashboard
Manage Tickers

RHHBYROCHE HOLDING LTD

N/A


$ 0.05 (0.16 %)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 442.84 $ 1.02 (0.23 %)
DIA $ 394.52 $ -0.72 (-0.18 %)
SPY $ 520.61 $ 0.07 (0.01 %)
TLT $ 90.36 $ 0.23 (0.26 %)
GLD $ 216.28 $ -2.45 (-1.12 %)
$ 30.95
-- x --
-- x --
-- - --
$ 29.20 - $ 38.83
1,519,135
na
0
$ 0.47
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

why-is-penny-stock-hookipa-pharma-trading-higher-on-wednesday
Why Is Penny Stock HOOKIPA Pharma Trading ...
04/24/2024 14:31:37

HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about ...

Core News & Articles
Roche Announces Genentech's Subcutaneous O...
04/17/2024 06:09:55

Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated nea...

roches-lymphoma-drug-with-chemo-extends-survival-in-pretreated-patients
Roche's Lymphoma Drug With Chemo Extends S...
04/15/2024 12:56:25

Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + G...

Core News & Articles
Roche's Genentech Announces That Columvi M...
04/15/2024 05:34:28

Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for peopl...

Core News & Articles
Roche Obtains CE Mark For First Companion ...
04/10/2024 06:50:43

Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2.1 Patients with HER2-low s...

analysts-express-confidence-in-alnylams-hypertension-drug-despite-mixed-trial-data
Analysts Express Confidence in Alnylam's H...
04/08/2024 18:37:35

The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in tr...

why-is-european-pharma-giant-argenx-valued-at-over-20b-trading-higher-on-thursday
Why Is European Pharma Giant Argenx Valued...
03/21/2024 15:06:51

Argenx shares rise on Chugai's gMG trial disappointment. FDA-approved Vyvgart for anti-acetylcholine receptor antibody-posi...

swiss-healthcare-manufacturing-firm-lonza-bolsters-biologics-manufacturing-capacity-with-roches-us-facility-acquisition-for-12b
Swiss Healthcare Manufacturing Firm Lonza ...
03/20/2024 16:38:42

Lonza expands biologics manufacturing capacity with acquisition of Genentech facility in Vacaville, CA. $1.2 billion deal inclu...

fda-approves-beigenes-first-drug-candidate-produced-through-its-immuno-oncology-program-for-esophageal-cancer
FDA Approves BeiGene's First Drug Candidat...
03/15/2024 17:01:52

FDA approves BeiGene's Tevimbra for esophageal squamous cell carcinoma, offering hope for patients after prior chemotherapy...

Core News & Articles
Roche Unveils navify Analytics For Optimal...
03/12/2024 07:11:58

Roche introduces its suite of navify operational excellence solutions, including navify Analytics and navify Monitoring, for ...

top-wall-street-analysts-flag-us-market-concentration-anxiety-advise-investors-to-adopt-barbell-approach
Top Wall Street Analysts Flag US Market Co...
03/11/2024 14:38:34

Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, ...

fda-conditionally-approves-expanded-use-of-beigenes-combination-drug-for-certain-type-of-blood-cancer
FDA Conditionally Approves Expanded Use Of...
03/08/2024 15:02:38

FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination ...

rochealnylam-blood-pressure-drug-aces-in-mid-stage-trial-analyst-says-zilebesiran-as-promising-opportunity-in-addressing-global-hypertension-challenges
Roche/Alnylam Blood Pressure Drug Aces In ...
03/05/2024 19:38:20

Alnylam's KARDIA-2 Phase 2 study on zilebesiran, an RNAi therapeutic for hypertension. Clinically significant reductions in...

Core News & Articles
Alnylam And Roche Initiated KARDIA-3 Phase...
03/05/2024 12:42:31

Core News & Articles
Alnylam/Roche Report KARDIA-2 Topline Stud...
03/05/2024 12:40:59

11-granolas-stocks-outperform-magnificent-7-with-lower-volatility-higher-yields
11 'Granolas' Stocks Outperform Magnificen...
02/28/2024 19:43:26

A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index ...

roche-explores-selling-lung-disease-drug-amid-buyer-interest---bloomberg-news
'Roche Explores Selling Lung Disease Drug ...
02/26/2024 16:40:26

https://www.bloomberg.com/news/articles/2024-02-26/roche-explores-selling-lung-disease-drug-amid-buyer-interestRoche Holding AG...

this-drug-by-roche-and-novartis-reduces-allergic-reactions-across-multiple-foods-for-people-with-food-allergies
This Drug By Roche And Novartis Reduces Al...
02/26/2024 15:52:06

Results from Roche's Phase 3 OUtMATCH study on Xolair for multi-food allergies. Published in NEJM, the study reveals increa...

Core News & Articles
Reported Earlier, Roche's Genentech Announ...
02/26/2024 08:11:53

– Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts...

fda-fast-tracks-review-of-sareptas-groundbreaking-muscular-dystrophy-treatment-with-1b-market-in-sight
FDA Fast-Tracks Review Of Sarepta's Ground...
02/16/2024 18:07:59

Sarepta's Elevidys efficacy supplement accepted for Duchenne muscular dystrophy treatment expansion, potential $1 billion y...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION